Key result
Polygenic risk scores aggregate genome-wide variants to identify dyslipidemia, assess CV risk, and guide therapy.
Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: To review current progress in the use of polygenic risk scores for lipid traits and their use in the diagnosis and treatment of lipid disorders. RECENT FINDINGS: Inherited lipid disorders, including those causing extremes of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides were initially identified as monogenic traits, in which a single rare variant with large effect size is responsible for the phenotype. More recently, a polygenic basis for many lipid traits has also been identified. Patients with polygenic dyslipidemia can be identified through the use of polygenic risk scores (PRSs), which collapse information from a handful to several million genetic variants into a single metric. SUMMARY: PRSs for lipid traits may aid in the identification of the genetic basis for the lipid phenotype in individual patients, may provide additional information regarding the risk of cardiovascular disease, and could help in guiding therapeutic decision making.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Dyslipidemia / lipid disorders. Polygenic risk scores (PRSs) was evaluated. Polygenic risk scores collapse information from several to millions of genetic variants to identify polygenic dyslipidemia, assess cardiovascular risk, and guide therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: